Skip to main content
Top
Published in: Journal of Cancer Education 4/2020

01-08-2020 | Computed Tomography

Occurrence of Discussion about Lung Cancer Screening Between Patients and Healthcare Providers in the USA, 2017

Authors: Samir Soneji, JaeWon Yang, Nichole T. Tanner, Gerard A. Silvestri

Published in: Journal of Cancer Education | Issue 4/2020

Login to get access

Abstract

Computed tomography lung cancer screening reduces lung cancer mortality. However, screening is underutilized. This study assesses the extent to which providers discuss lung cancer screening with their patients, as a lack of discussion and counseling may serve as a potential cause of low utilization rates. Data from 1667 adults aged 55–80 years sampled in the 2017 Health Information National Trends Survey was utilized. A weighted multivariable logistic regression model was fit with past-year discussion about lung cancer screening with a provider as the outcome. The adjusted odds of discussion were higher for current cigarette smokers compared to non-cigarette smokers (adjusted odds ratio = 3.91; 95% confidence interval [CI], 1.75 to 8.74). Despite higher odds, the absolute prevalence was low with only 18% (95% CI, 11.8 to 24.2%) of current adult smokers reporting a past-year discussion. Knowledge of screening from trusted sources of medical information, such as doctors, can increase screening rates and may ultimately reduce lung cancer mortality.
Appendix
Available only for authorised users
Literature
Metadata
Title
Occurrence of Discussion about Lung Cancer Screening Between Patients and Healthcare Providers in the USA, 2017
Authors
Samir Soneji
JaeWon Yang
Nichole T. Tanner
Gerard A. Silvestri
Publication date
01-08-2020
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 4/2020
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-019-01510-9

Other articles of this Issue 4/2020

Journal of Cancer Education 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine